Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Accumulated Expenses (2018 - 2025)

TransMedics has reported Accumulated Expenses over the past 8 years, most recently at $62.7 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $62.7 million for Q4 2025, up 38.95% from a year ago — trailing twelve months through Dec 2025 was $62.7 million (up 38.95% YoY), and the annual figure for FY2025 was $62.7 million, up 38.95%.
  • Accumulated Expenses for Q4 2025 was $62.7 million at TransMedics, up from $56.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for TMDX hit a ceiling of $62.7 million in Q4 2025 and a floor of $2.7 million in Q3 2023.
  • Median Accumulated Expenses over the past 5 years was $16.5 million (2022), compared with a mean of $23.3 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 83.21% in 2023 and later soared 1472.38% in 2024.
  • TransMedics' Accumulated Expenses stood at $5.2 million in 2021, then surged by 260.24% to $18.6 million in 2022, then soared by 105.1% to $38.2 million in 2023, then rose by 18.13% to $45.2 million in 2024, then soared by 38.95% to $62.7 million in 2025.
  • The last three reported values for Accumulated Expenses were $62.7 million (Q4 2025), $56.0 million (Q3 2025), and $17.0 million (Q2 2025) per Business Quant data.